|
Role of SLC13A3 in Renal Cell Carcinoma
|
5F31CA210612-03
|
$29,664
|
JORDAN, ANDRE
|
AUGUSTA UNIVERSITY
|
|
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma
|
5R01CA176691-05
|
$341,059
|
LOKESHWAR, VINATA
|
AUGUSTA UNIVERSITY
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
A New Target for Chromatin Remodeler Defects in Cancer
|
1R35CA231993-01
|
$594,375
|
WALKER, CHERYL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Combating Resistance to Antiangiogenic Therapy in Renal Cell Carcinoma
|
5R01CA196996-04
|
$398,025
|
BHATT, RUPAL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-14
|
$2,300,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
c-Met-induced Renalase: a novel therapeutic target for renal cancer
|
1R03CA219731-01A1
|
$88,500
|
BALAN, MURUGABASKAR
|
BOSTON CHILDREN'S HOSPITAL
|
|
Regulation of the LIN28/let-7 pathway in cancer
|
5R01CA211328-02
|
$404,888
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
Protective role of Honokiol in preventing c-Met-induced post-transplantation cancer
|
1R01CA222355-01
|
$411,068
|
PAL, SOUMITRO
|
BOSTON CHILDREN'S HOSPITAL
|
|
Novel Role(s) of Nrf2 in the Growth of Post-Transplantation Cancer
|
5R01CA193675-03
|
$404,888
|
PAL, SOUMITRO
|
BOSTON CHILDREN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S1
|
$3,249,644
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S2
|
$1,000,000
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-05
|
$8,073,787
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
The Metabolic Pathogenesis of Chromophobe Renal Cell Carcinoma
|
1R01CA216922-01A1
|
$426,489
|
HENSKE, ELIZABETH
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Spatiotemporal delivery of synergistic drug combinations to kidney cancer
|
1R01CA229772-01
|
$360,930
|
SABBISETTI, VENKATA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-28
|
$5,637,954
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-28S1
|
$249,965
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Contribution of Gynecologic and Breast Cancer Biospecimens from African American women to HCMI
|
3P30CA043703-28S2
|
$48,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-05
|
$1,187,291
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A Patient-Centered Approach to Integration of Life Expectancy into Treatment Decision Making for Patients with Genitourinary Malignancy
|
1K08CA230155-01
|
$183,258
|
DASKIVICH, TIMOTHY
|
CEDARS-SINAI MEDICAL CENTER
|
|
A Unique Deployable Thermosensor Probe for the Minimally Invasive Treatment of Renal Tumors
|
1R43CA224431-01A1
|
$300,000
|
VAN BUSKIRK, ROBERT
|
CELL PRESERVATION SERVICES, INC.
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-05
|
$192,024
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-05
|
$20,853,800
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Pre-IND development of CBT-15 monoclonal antibody therapy against renal cell cancer
|
1R44CA228895-01A1
|
$298,835
|
SUREBAN, SRIPATHI
|
COARE HOLDINGS, INC.
|
|
Defining the functions and translational potential of ferroptosis
|
5R35CA209896-03
|
$955,184
|
STOCKWELL, BRENT
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Cancer Center Support Grant
|
3P30CA013696-44S1
|
$120,000
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S2
|
$60,000
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant - PDXNet Supplement
|
3P30CA013696-44S3
|
$126,563
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S4
|
$191,726
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S5
|
$237,191
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S6
|
$246,815
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S7
|
$224,982
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S8
|
$126,563
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S9
|
$250,000
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-44
|
$3,972,720
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
|
5U10CA180867-05
|
$1,302,199
|
BURSTEIN, HAROLD
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S1
|
$445,796
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S2
|
$59,495
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S3
|
$62,500
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S4
|
$149,528
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S5
|
$60,691
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S6
|
$228,108
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S7
|
$199,806
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
5P30CA006516-53
|
$11,504,298
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
New Paradigms for Targeting Truncal Driver Mutations
|
5R35CA210068-03
|
$972,607
|
KAELIN, WILLIAM
|
DANA-FARBER CANCER INST
|
|
Physical detection of HLA-C binding peptides to identify and predict immunogenic personal neoepitopes for improving cancer vaccines
|
1R21CA216772-01A1
|
$232,224
|
KESKIN, DERIN
|
DANA-FARBER CANCER INST
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|